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data source to identify patients with AS and their insurance claim records in 2013 
for in-patient care and out-patient care. The identified patients were stratified by 
AS-related medications for the comparisons on drug costs and non-drug medical 
costs. Generalized linear model (GLM) was conducted to assess the impact of the 
classified medications on on-drug medical costs after full adjustment of patient 
baseline characteristics including demography, AS-related to complications, and 
comorbidities. Results: Among the identified 1299 patients with diagnosed AS, the 
AS-related medications included nonsteroidal anti-inflammatory drugs (NSAIDs) 
(n= 234), immunosuppressant (n= 146), combination of NSAID and immunosuppres-
sant (n= 626), biologics (n= 60), and Chinese medications (n= 233). The total medical 
costs associated with AE-related treatments ranged from RMB 4,565 for Chinese 
medication to RMB 24,585 for biologics treatment (1 RMB = 0.16 US$). However, bio-
logics treatment and the combination treatment of NSAID and immunosuppressant 
had similar non-drug medical costs (RMB 7,039 versus RMB 7,450, p= 0.164). GLM 
regression analysis further confirmed highly comparable non-drug medical costs 
associated with biologics (coefficient: 0.0639, p = 0.741) relative to the combination 
treatment of NSAID and immunosuppressant. ConClusions: Among publically 
insured Chinese patients with AS, biologics treatments were associated with highly 
comparable non-drug medical costs as the combination treatment of NSAID and 
immunosuppressant. This finding suggests that biologics may effectively control 
health resource utilization through their superior treatment effects.
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objeCtives: The aim of this study was to assess the indirect costs caused by absen-
teeism associated with psoriatic and enteropathic arthropathies from the perspective 
of the Social Insurance Institution (ZUS) in Poland. Methods: The estimates were 
based on data from the year 2013 concerning sick leave and the amount of short-
term disability, the sufferers of which claim rehabilitation benefit, and the amount of 
long-term disability (permanent or fixed time), the sufferers of which claim disability 
pension. Costs calculated taking into account Gross Domestic Product (GDP) per capita 
equaled € 10 278, Gross Value Added (GVA) per worker equaled € 24 680 and Gross 
Income (GI) per worker equaled € 7 339 were presented in 2013 prices. Results: Total 
indirect costs of psoriatic and enteropathic arthropathies in the year 2013 calculated 
using GDP per capita, GVA and GI per worker in Poland were € 7 341 217, € 17 628 441 
and € 5 242 346, respectively. The highest component of indirect costs was permanent 
long-term disability (43%). Fixed period long-term disability and short-term disability 
costs constitute 20% and 9% of total indirect costs, respectively. In 2013 Poland’s Social 
Insurance Institution database reported 2 100 patients that had 4 922 sick leave epi-
sodes, 180 short-term disability episodes and 80 long-term disability episodes. Indirect 
costs per patient associated with sick leave were € 1 030, € 2 474 and € 736 calculated 
using GDP, GVA and GI, respectively. Indirect costs per patient associated with short-
term disability were € 298, € 715 and € 212 respectively and associated with long-term 
disability were as high as € 2 168, € 5 206 and € 1 548, respectively. ConClusions: 
Psoriatic and enteropathic arthropathies in Poland generated high indirect costs. The 
main component was permanent long-term disability; short-term disability gener-
ated lower costs of lost productivity. The highest cost per patient was generated by 
permanent long-term disability.
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objeCtives: To estimate the direct cost of Del5q MDS from the perspective of 
the public healthcare system in Mexico Methods: We evaluated the amount of 
resources utilized by patients with Del5q MDS from an expert panel of eight hema-
tologist through the Delphi technique. Consensus was reached after two expert 
panel rounds and patterns of use were analyzed statistically. Unit costs of resources 
were extracted from institutional catalogues and annual cost estimations were 
performed for different health states. All values were expressed in US dollars of 
2015 Results: From the consensus of panel experts we found that management 
of patients with Del5q MDS at Mexican public healthcare institutions consisted 
of best supportive care with red blood cell (RBC) transfusions and erythropoiesis-
stimulating agents, and since these patients are RBC-transfusion dependent, they 
receive 33 units of RBC per year resulting in a cost of US$5,265.60. Iron overload is 
the main complication of transfusion dependency resulting in an annual cost of 
US$1,782.11 attributable to congestive heart failure. Other resources used to the 
treatment of the disease are drugs, labs, and visits that contribute to the total annual 
cost of US$30,647.78 per patient ConClusions: MDS patients with 5q deletion 
impose a high economic burden to the public healthcare system in Mexico, although 
the incidence is lower than other hematological malignancies
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Generalized Linear Models (log link, Gamma family) adjusting for gender, age, BMI, 
type of intervention, complications and comorbidites. Costs are expressed in Euro 
2013. Results: 280 patients (171 workers, 61%, and 109 no-workers including peo-
ple out of work, students, housewives and retirees, 39%) have been submitted to bar-
iatric surgery and followed up to 1 year after the intervention. The overall social cost, 
including costs of intervention and 1-year follow up, was € 11,310 (± € 3,778). Direct 
medical costs amounted to € 8,737 (± 2,527), representing the 77% of the overall cost, 
while direct non medical costs and indirect costs accounted for 13% and 10% (€ 1.497 
± € 1,928 and € 1,076 ± € 1,675). No working conditions had an incremental effect on 
direct non-medical costs of € 676 (95% CI: € 212-€ 1,140, p= 0.004). Working conditions 
increased indirect costs by € 1,384 (95% CI: € 1,002-€ 1,766, p= 0.000). ConClusions: 
Socio-economic determinant such as employment status of patient led to significant 
impacts on direct non medical costs and indirect costs of a patient submitted to 
bariatric surgery.
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objeCtives: The aim of this study was to assess the indirect costs caused by absen-
teeism associated with inflammatory bowel disease (IBD) - (Crohn’s disease – CD; 
and ulcerative colitis - UC) from the perspective of the Social Insurance Institution 
(ZUS) in Poland Methods: The estimates were based on data provided by ZUS 
referring to year 2013 and concerning absence from work due to the illness (sick 
leave), the amount of short-term disability, the sufferers of which claim rehabilita-
tion benefit, and the amount of permanent (or long-term) disability, the sufferers of 
which claim disability pension. Costs were calculated with Human Capital Approach 
methodology taking into account Gross Domestic Product (GDP) per capita equaled 
€ 10 278. Results: Total indirect costs of CD, UC in the year 2013 calculated using 
GDP per capita in Poland were € 7 817 156 and € 8 990 313, respectively. Total indirect 
costs of IBD in the year 2012 and 2013 in Poland were € 14 220 181 and € 16 807 469, 
respectively (an increase of nearly 15% because of substantial growth short-term 
disabilities). The highest component of indirect costs of IBD was sick leave (51%). 
Long and short-term disability costs constitute 39% (limited period – 19% and unlim-
ited period 20%) and 10% of total indirect costs of IBD, respectively. One sick leave of 
person with IBD generated the cost of lost productivity equal € 779 calculated using 
GDP per capita. Indirect cost of short-term disability for one entitlement to the ben-
efit of rehabilitation were € 7 314. Cost of one long-term benefit were much higher 
than short-term benefit and equaled for limited period € 36 714 and unlimited period 
€ 941. Total long-term disability costs amounted € 676 651. ConClusions: IBD in 
Poland generated high indirect costs. The main component was sick leave; reha-
bilitation benefit and disability pension generated lower costs of lost productivity.
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objeCtives: Idiopathic pulmonary fibrosis (IPF) is a chronic, fibro-proliferative 
and fatal lung disease. A study was conducted to describe the causes and main 
comorbidities of hospitalized patients and associated costs in France. Methods: 
A retrospective, observational study was set up using the French hospital discharge 
database (PMSI). Patients with a first hospitalization for IPF (ICD-10 code: J841) in 
2008 were identified and followed during a 5-year period. As J841 code includes 
other fibrotic pulmonary diseases, an algorithm for data extraction was defined, 
with exclusion of age< 50 and presence of a differential diagnosis in the follow-
ing year (connective disease or pneumoconiosis). Patient characteristics, first stay 
and occurrence of events of special interest were described as well as associated 
costs. Results: In 2008, 6,476 patients newly hospitalized for IPF were identified, 
with a mean age of 75.4±10.3 years, and 56% were men. The mean total cost of 
hospitalizations per patient for the 5-year follow-up period was € 15,532±15,973. 
Main cost drivers were the serious events related to the disease, specifically acute 
exacerbation (37% of patients, with a 10% in-hospital mortality rate and a cost of 
€ 4,091±4,429/event), cardiac events (48% of patients with a 14% in-hospital mortality 
rate and a cost of € 5,731±5,463/event), acute respiratory infections (44% of patients 
with a 18% in-hospital mortality rate and a cost of € 7,471±7,981/event) and arterial 
thrombosis (12% of patients with a 20% in-hospital mortality rate and a cost of 
€ 7,467±7,216/event). Finally, 11% of patients received palliative care with a mean 
cost for the last year of life of € 14,807±11,979 per deceased patient. ConClusions: 
This study is the first providing extensive data on hospital management for patients 
with IPF in France, demonstrating high burden and hospital cost, especially for acute 
respiratory deteriorations. These results could be used in economic evaluations for 
IPF patients in France.
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objeCtives: To estimate direct medical costs associated with ankylosing spondyli-
tis (AS) in publically insured Chinese patients. Methods: China Health Insurance 
Research Association (CHIRA) claim data containing patients randomly selected 
from publically insured urban residents and workers across China was used as the 
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using the survey results and findings from the literature: cost of travel to receive 
healthcare (£780), household expenses (£136), cost of moving home (£65) and lost 
accommodation costs (£214). ConClusions: Patient survey results showed that 
aHUS has a substantial economic burden to patients, their carers and society. The 
total economic burden from lost productivity of patients, carers and out-of-pocket 
expenses was estimated to be £9,243 per aHUS patient per year.
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objeCtives: In the United States (US), the 1983 Orphan Drug Act (ODA) established 
incentives for the development of drugs that treat rare or orphan diseases (defined 
as diseases affecting < 200,000 Americans). Health Canada is currently developing 
an orphan drug framework (for diseases affecting ~5 in 10,000 Canadians). This study 
measured total annual expenditures of orphan drugs in the US and Canada (2007-
13) and estimated future (2014-18) orphan drug expenditures. Methods: Branded, 
orphan drugs approved by the US Food and Drug Administration (FDA) between 
1983-2013 were identified (N= 356). The Canadian analysis only included US orphan 
drugs with the same orphan indication(s) approved in Canada. Adjustment via dis-
ease factoring was applied to products with multiple indications (both orphan and 
non-orphan) using available data sources to isolate orphan-indication sales only. 
The IMS MIDAS database was used to assess total orphan drug expenditures, calcu-
lated annually from 2007-2013 and evaluated as a proportion of total annual phar-
maceutical drug expenditures (all reported in 2014 US dollars). Results: Between 
2007-2013, expenditures were measured for a final N= 316 and N= 147 orphan 
drugs in the US and Canada, respectively. In the US, total orphan drug expendi-
tures accounted for $15.0-$30.0 billion in 2007-13, representing 4.8-8.9% of total U.S. 
pharmaceutical expenditures, respectively. In Canada, orphan drug expenditures 
totaled $557.7-$1,005.8 million in 2007-13, representing 3.3-5.6% of total Canadian 
pharmaceutical expenditures, respectively. Future trend analysis (2014-18) suggests 
a slowing down in growth of orphan drug expenditures. ConClusions: While the 
number of available orphan drugs and associated expenditures increased over time, 
these drugs benefit many people with previously underserved rare conditions. From 
a societal perspective, the overall budget impact of orphan drugs is small and has 
remained fairly stable relative to total pharmaceutical expenditures. Concerns that 
growth in orphan drug expenditures may lead to unsustainable drug expenditures 
do not appear to be justified.
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objeCtives: The development of inhibitors is the most challenging complication of 
hemophilia treatment. Bypassing agents (i.e. aPCC and rFVIIa) remain the therapy 
of choice but account for a significant proportion of treatment cost. This study 
aims to compare the cost-effectiveness of aPCC vs. rFVIIa in on-demand treat-
ment from the Brazilian public health system perspective. Methods: A literature 
based cost model was developed based on utilization and efficacy (evaluated at 2, 
6, 12, 24, 36 and 48 hours after infusion) data from the FENOC (head-to-head) trial 
which investigated the equivalency of the clinical efficacy of aPCC and rFVIIa in 
on-demand treatment. The median (range) treatment dose was 84.6 (51.5-100) U/kg 
and 212.5 (98.6-261.8) µg/kg for aPCC and rFVIIa, respectively. Hemostatic efficacy 
ranged from 75% to 97.6% for aPCC and 60.4% to 85.4% for rFVIIa. Bleed resolution 
rate also ranged from 53.2% to 95.1% for aPCC and 38.3% to 92.7% for rFVIIa. Cost 
analysis was limited to drug costs and prices were obtained from the 2014 Brazilian 
Official Diary: U$0.71/U and U$0.64/µg for aPCC and rFVIIa, respectively. One-way 
sensitivity analyses were performed to determine model robustness when dose and 
price were varied by ±25%. Results: The cost/kg per on-demand bleed treatment 
was 55.9% lower for aPCC compared to rFVIIa. The cost/kg per treatment efficacy 
was 64% to 79% lower for aPCC compared to rFVIIa. Similarly, cost/kg per resolved 
bleed was 68% to 81% lower for aPCC compared to rFVIIa. Results remained robust 
for all one-way sensitivity analyses conducted. Given, an estimated total inhibitor 
population of 684 in Brazil, total saving with aPCC can vary from U$13.2-U$53.2 mil-
lion depending on market share. ConClusions: aPCC was the dominant therapy 
in on-demand treatment. Using the current Brazilian prices, for each bleed treated 
with rFVIIa about 2.3 bleeds could be treated with aPCC at comparable cost.
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objeCtives: Treatment of Cystic Fibrosis (CF) as rare disease is generally perceived 
as highly expensive, but we did not have more specific national or local costs data. 
Since patients are on lifelong treatment we tried to analyzed direct costs associated 
with CF in single center. Methods: We analyze direct costs associated with treat-
ment management of patients with CF in selected center in Slovakia from 2009 till 
2013. We reviewed 182 adult patients regularly visiting CF centrum. We distributed 
patients according to age that is closely connected with CF prognosis. We included: 
treatment costs, healthcare procedures, medical devices and hospitalization costs. 
We used perspective of healthcare provider. We chose cost-of-illness, prevalence-
based approach and compared costs based on time/year, gender, age and type of 
procedure. Results: We have found that adult patients with CF between age 30 and 
35 (21 patients) consumed most resources from 2009 till 2012, but most significantly 
objeCtives: BTcP is associated with a number of problematic physical, psycholog-
ical/emotional and social complications which themselves are not only a relevant 
source of additional morbidity in these patients, but are also responsible for sig-
nificant economic implications, for the patient, their relatives, for the healthcare 
system and society. Methods: We performed a systematic literature search of 
PubMed electronic database through December 2014 and February 2015. The key 
words included “breakthrough cancer pain” and “cost effectiveness” or “econom-
ics” or “pharmacoeconomic,” and MeSH terms included “breakthrough pain” and 
“neoplasms”, or “economics” or “cost-benefit analysis” . There were no language 
or study design restrictions. A total of 20 articles were identified. Among the 10 
included studies, there were two quality improvement projects, two survey studies, 
three decision-analytic models, one literature review, two pharmacoeconomics 
studies and one health economic framework. Results: BTcP is associated with 
increased medical costs: direct medical costs, indirect costs, intangible cost. Direct 
medical costs might include hospital charges, cost of analgesics and other medica-
tions, radiotherapy, surgery, and clinician time; direct non-medical costs might 
include the cost of gas to drive to the clinic, parking during a clinic visit, highway 
tolls, overnight lodging for family/caregivers, meals for caregivers. Intangible 
costs include the patient’s pain, suffering, depression, anxiety, loss of sleep, 
and fatigue, as well as the family’s and/or caregiver’s distress. ConClusions: 
Additional studies are needed to evaluate quality-of-life improvements and the 
cost-effectiveness of more systematic analgesic treatments for BTcP. By delineat-
ing all the factors describing the impact of BTcP on patients, providers, and society, 
a comprehensive health economic model will improve clinical decision making, 
optimize outcomes, and enhance satisfaction with the processes of care across all 
stakeholder levels. In the case of HTA in breakthrough cancer pain, ethical evalu-
ations appear to be the most important assessment focus among the considered 
ones.
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objeCtives: Familial Mediterranean Fever disease (FMF) is an autosomal reces-
sively inherited disease characterized by recurrent, self-limited febrile attacks with 
serositis, synovitis, and occasionally skin involvement. AA amyloidosis is the most 
serious complication of FMF and can be life-threatening. Daily colchicine is consid-
ered standard of care, and is expected to prevent attacks and amyloidosis in most 
patients. The objective of this study is to estimate the cost burden of FMF in Turkey 
from payer perspective. Methods: Delphi technique was applied to determine 
the type and the amount of resources used in FMF based on physicians views. The 
Delphi method solicits the opinion of an expert panel through a carefully designed 
questionnaire which in this case included questions on: type, frequency and dura-
tion of the health care resources used for diagnosis and treatment of the disease, 
epidemiology of the disease and colchicine resistant patients. Ten key opinion 
experts were involved in the study.The responses were analysed and discussed in 
a face to face meeting followed by consensus building steps. Unit costs of resources 
used were obtained from payer’ Reimbursement Guideline-List of Procedure Fees Per 
Service. Results: The prevalence of the disease is estimated 0.1%. 65% of patients 
are responders to colchicine treatment, 30% are partial responders and 2-5% are 
colchicine resistant. The cost of diagnosis was 549,59TL, cost of standard treatment 
was 3.233,86TL, cost of treatment for colchicine resistant patients was 69.254,32TL 
per patient. The cost of treatment of two major complications, amyloidosis and 
renal failure were estimated as 8.628,98TL and 16.120TL respectively. The annual 
total cost of the disease to the SSI was found as 547.945.305TL without complications 
and 750.921.801TL with complications. ConClusions: FMF is highly prevalent in 
Turkey and there are unmet needs for colchicine resistant patients. The burden 
of disease is increasing with long term complications and colchicine resistance.
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bACkgRound: Atypical haemolytic uraemic syndrome (aHUS) is a progressive, life-
threatening, and ultra-rare disease with an estimated prevalence of 5.5 persons 
per million in England (AGNSS in 2012). objeCtives: There is a lack of literature 
describing the economic and humanistic burden of aHUS. A patient survey was 
undertaken to evaluate the impact of aHUS on patients, their carers and society in 
the UK. Methods: aHUS patients and their carers were recruited by the UK aHUS 
Patients and Families Support Group and were asked to complete an online ques-
tionnaire. Respondents described the impact of aHUS on daily activities, work and 
out-of-pocket expenses. Results: 37 patients with aHUS completed the survey. 
23 patients were above 18 years of age (23/35). 61% of adult patients (14/23) were 
employed, 39% (9/23) were not currently in employment; of these, 33% (3/9) were 
retired. The rate of economically inactive adults among aHUS patients exceeded 
the UK national average by 20%. Based on the UK median earning (ONS 2012), an 
annual lost productivity cost of £2,650 per aHUS patient or £472 of lost tax rev-
enues was calculated. 54% (20/37) of aHUS patients had a carer, of which 82% (16/20) 
were informal carers (ie. family members). On average, carers lost 18 hours of paid 
work per week and estimated £12,190 lost productivity/£2,170 lost tax revenues per 
carer. The following out-of-pocket expenses (per patient per year) were estimated 
